Predicting Anti-TNF-Therapy Responsiveness

Research reveals a defect in myosin binding to TNFR2-M196R causes TNF-independent proinflammatory activity. The ability to genotype this polymorphism should help to predict inadequate responders to anti-TNF therapies early on, and allowing a personalized approach to the treatment of rheumatoid and psoriatic diseases.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Advertising Policy